Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, 74, 2913, 10.1158/0008-5472.CAN-14-0155 Siegel, 2021, Cancer Statistics, 2021, CA Cancer J Clin, 71, 7, 10.3322/caac.21654 Kommalapati, 2018, Contemporary management of localized resectable pancreatic cancer, Cancers (Basel), 10, 24, 10.3390/cancers10010024 Basturk, 2015, A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas, Am J Surg Pathol, 39, 1730, 10.1097/PAS.0000000000000533 Winter, 2006, 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience, J Gastrointest Surg, 10, 1199, 10.1016/j.gassur.2006.08.018 Felsenstein, 2018, IPMNs with co-occurring invasive cancers: neighbours but not always relatives, Gut, 67, 1652, 10.1136/gutjnl-2017-315062 Zamboni, 1999, Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors, Am J Surg Pathol, 23, 410, 10.1097/00000478-199904000-00005 Laffan, 2008, Prevalence of unsuspected pancreatic cysts on MDCT, AJR Am J Roentgenol, 191, 802, 10.2214/AJR.07.3340 Grimont, 2021, Uncertain beginnings: acinar and ductal cell plasticity in the development of pancreatic cancer, Cell Mol Gastroenterol Hepatol, 13, 369, 10.1016/j.jcmgh.2021.07.014 Matsuda, 2017, The prevalence and clinicopathological characteristics of high-grade pancreatic intraepithelial neoplasia: autopsy study evaluating the entire pancreatic parenchyma, Pancreas, 46, 658, 10.1097/MPA.0000000000000786 Andea, 2003, Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma, Mod Pathol, 16, 996, 10.1097/01.MP.0000087422.24733.62 Rezaee, 2016, Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma, HPB (Oxford), 18, 236, 10.1016/j.hpb.2015.10.010 Oyama, 2020, Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms, Gastroenterology, 158, 226, 10.1053/j.gastro.2019.08.032 Furukawa, 2005, Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study, Virchows Archiv, 447, 794, 10.1007/s00428-005-0039-7 Noë, 2020, Genomic characterization of malignant progression in neoplastic pancreatic cysts, Nat Commun, 11, 4085, 10.1038/s41467-020-17917-8 Luchini, 2016, Pancreatic ductal adenocarcinoma and its variants, Surg Pathol Clin, 9, 547, 10.1016/j.path.2016.05.003 Groot, 2018, Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma, Ann Surg Oncol, 25, 2475, 10.1245/s10434-018-6558-7 Wangjam, 2015, Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns, Oncotarget, 6, 36903, 10.18632/oncotarget.5054 Iacobuzio-Donahue, 2009, DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer, J Clin Oncol, 27, 1806, 10.1200/JCO.2008.17.7188 Almoguera, 1988, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, 53, 549, 10.1016/0092-8674(88)90571-5 Scarpa, 1993, Pancreatic adenocarcinomas frequently show p53 gene mutations, Am J Pathol, 142, 1534 Caldas, 1994, Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma, Nat Genet, 8, 27, 10.1038/ng0994-27 Hahn, 1996, DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1, Science, 271, 350, 10.1126/science.271.5247.350 Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 Biankin, 2012, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes, Nature, 491, 399, 10.1038/nature11547 Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 Waddell, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169 2017, Integrated genomic characterization of pancreatic ductal adenocarcinoma, Cancer Cell, 32, 185, 10.1016/j.ccell.2017.07.007 2020, Pan-cancer analysis of whole genomes, Nature, 578, 82, 10.1038/s41586-020-1969-6 Notta, 2016, A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns, Nature, 538, 378, 10.1038/nature19823 Hata, 2018, Genome-wide somatic copy number alterations and mutations in high-grade pancreatic intraepithelial neoplasia, Am J Pathol, 188, 1723, 10.1016/j.ajpath.2018.03.012 Makohon-Moore, 2018, Precancerous neoplastic cells can move through the pancreatic ductal system, Nature, 561, 201, 10.1038/s41586-018-0481-8 Yachida, 2010, Distant metastasis occurs late during the genetic evolution of pancreatic cancer, Nature, 467, 1114, 10.1038/nature09515 Makohon-Moore, 2017, Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer, Nat Genet, 49, 358, 10.1038/ng.3764 Kuboki, 2019, Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions, J Pathol, 247, 347, 10.1002/path.5194 Fischer, 2019, Intraductal papillary mucinous neoplasms arise from multiple independent clones, each with distinct mutations, Gastroenterology, 157, 1123, 10.1053/j.gastro.2019.06.001 Fujikura, 2020, Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions, Gut, 70, 928, 10.1136/gutjnl-2020-321217 Hosoda, 2017, Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4, J Pathol, 242, 16, 10.1002/path.4884 Pea, 2017, Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, Ann Surg, 266, 133, 10.1097/SLA.0000000000001817 Omori, 2019, Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features, Gastroenterology, 156, 647, 10.1053/j.gastro.2018.10.029 Schutte, 1997, Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas, Cancer Res, 57, 3126 Vincent, 2011, Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma, Clin Cancer Res, 17, 4341, 10.1158/1078-0432.CCR-10-3431 McDonald, 2017, Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis, Nat Genet, 49, 367, 10.1038/ng.3753 Fukushima, 2002, Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma, Am J Pathol, 160, 1573, 10.1016/S0002-9440(10)61104-2 Sato, 2008, CpG island methylation profile of pancreatic intraepithelial neoplasia, Mod Pathol, 21, 238, 10.1038/modpathol.3800991 Sato, 2002, Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas, Gastroenterology, 123, 365, 10.1053/gast.2002.34160 Fujikura, 2021, Downregulation of 5-hydroxymethylcytosine is an early event in pancreatic tumorigenesis, J Pathol, 254, 279, 10.1002/path.5682 Moffitt, 2015, Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat Genet, 47, 1168, 10.1038/ng.3398 Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat Med, 17, 500, 10.1038/nm.2344 Puleo, 2018, Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features, Gastroenterology, 155, 1999, 10.1053/j.gastro.2018.08.033 Chan-Seng-Yue, 2020, Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution, Nat Genet, 52, 231, 10.1038/s41588-019-0566-9 Connor, 2019, Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases, Cancer Cell, 35, 267, 10.1016/j.ccell.2018.12.010 Raghavan, 2021, Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer, Cell, 184, 6119, 10.1016/j.cell.2021.11.017 Hayashi, 2020, A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma, Nature Cancer, 1, 59, 10.1038/s43018-019-0010-1 Topham, 2021, Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics, Clin Cancer Res, 27, 150, 10.1158/1078-0432.CCR-20-2831 Herting, 2021, The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions, Cancer Metastasis Rev, 40, 675, 10.1007/s10555-021-09988-w Lesina, 2011, Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer, Cancer Cell, 19, 456, 10.1016/j.ccr.2011.03.009 Karamitopoulou, 2019, Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features, Br J Cancer, 121, 5, 10.1038/s41416-019-0479-5 Ho, 2020, The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities, Nat Rev Clin Oncol, 17, 527, 10.1038/s41571-020-0363-5 Heumann, 2021, Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance, Cancer Metastasis Rev, 40, 837, 10.1007/s10555-021-09981-3 Helms, 2020, Fibroblast heterogeneity in the pancreatic tumor microenvironment, Cancer Discov, 10, 648, 10.1158/2159-8290.CD-19-1353 Elyada, 2019, Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts, Cancer Discov, 9, 1102, 10.1158/2159-8290.CD-19-0094 Feig, 2013, Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer, Proc Natl Acad Sci U S A, 110, 20212, 10.1073/pnas.1320318110 Francescone, 2021, Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression, Cancer Discov, 11, 446, 10.1158/2159-8290.CD-20-0775 Rhim, 2014, Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma, Cancer Cell, 25, 735, 10.1016/j.ccr.2014.04.021 Lee, 2014, Stromal response to Hedgehog signaling restrains pancreatic cancer progression, Proc Natl Acad Sci U S A, 111, E3091, 10.1073/pnas.1411679111 De Jesus-Acosta, 2020, Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma, Br J Cancer, 122, 498, 10.1038/s41416-019-0683-3 Catenacci, 2015, Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer, J Clin Oncol, 33, 4284, 10.1200/JCO.2015.62.8719 Ohlund, 2017, Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer, J Exp Med, 214, 579, 10.1084/jem.20162024 Biffi, 2019, IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma, Cancer Discov, 9, 282, 10.1158/2159-8290.CD-18-0710 Steele, 2021, Inhibition of Hedgehog signaling alters fibroblast composition in pancreatic cancer, Clin Cancer Res, 27, 2023, 10.1158/1078-0432.CCR-20-3715 Banh, 2020, Neurons release serine to support mRNA translation in pancreatic cancer, Cell, 183, 1202, 10.1016/j.cell.2020.10.016 Saloman, 2016, Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer, Proc Natl Acad Sci U S A, 113, 3078, 10.1073/pnas.1512603113 Renz, 2018, β2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer, Cancer Cell, 33, 75, 10.1016/j.ccell.2017.11.007 Klein, 2021, Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors, Nat Rev Gastroenterol Hepatol, 18, 493, 10.1038/s41575-021-00457-x Momi, 2012, Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis, Carcinogenesis, 33, 1617, 10.1093/carcin/bgs186 Hassan, 2007, Risk factors for pancreatic cancer: case-control study, Am J Gastroenterol, 102, 2696, 10.1111/j.1572-0241.2007.01510.x Sah, 2013, New insights into pancreatic cancer-induced paraneoplastic diabetes, Nat Rev Gastroenterol Hepatol, 10, 423, 10.1038/nrgastro.2013.49 Maitra, 2018, A prospective study to establish a new-onset diabetes cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer, Pancreas, 47, 1244, 10.1097/MPA.0000000000001169 Chari, 2005, Probability of pancreatic cancer following diabetes: a population-based study, Gastroenterology, 129, 504, 10.1016/j.gastro.2005.05.007 Chen, 2021, Validation of the enriching new-onset diabetes for pancreatic cancer model in a diverse and integrated healthcare setting, Dig Dis Sci, 66, 78, 10.1007/s10620-020-06139-z Sharma, 2018, Model to determine risk of pancreatic cancer in patients with new-onset diabetes, Gastroenterology, 155, 730, 10.1053/j.gastro.2018.05.023 Bracci, 2012, Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms, Mol Carcinog, 51, 53, 10.1002/mc.20778 Berrington de Gonzalez, 2003, A meta-analysis of obesity and the risk of pancreatic cancer, Br J Cancer, 89, 519, 10.1038/sj.bjc.6601140 Michaud, 2001, Physical activity, obesity, height, and the risk of pancreatic cancer, JAMA, 286, 921, 10.1001/jama.286.8.921 Kirkegård, 2017, Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis, Am J Gastroenterol, 112, 1366, 10.1038/ajg.2017.218 Weissman, 2020, The diverse involvement of cigarette smoking in pancreatic cancer development and prognosis, Pancreas, 49, 612, 10.1097/MPA.0000000000001550 Giardiello, 1987, Increased risk of cancer in the Peutz-Jeghers syndrome, N Engl J Med, 316, 1511, 10.1056/NEJM198706113162404 Goldstein, 1995, Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations, N Engl J Med, 333, 970, 10.1056/NEJM199510123331504 Rebours, 2008, Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series, Am J Gastroenterol, 103, 111, 10.1111/j.1572-0241.2007.01597.x Teich, 2006, Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis, Hum Mutat, 27, 721, 10.1002/humu.20343 Petersen, 2015, Familial pancreatic adenocarcinoma, Hematol Oncol Clin North Am, 29, 641, 10.1016/j.hoc.2015.04.007 Klein, 2013, Identifying people at a high risk of developing pancreatic cancer, Nat Rev Cancer, 13, 66, 10.1038/nrc3420 Roberts, 2016, Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer, Cancer Discov, 6, 166, 10.1158/2159-8290.CD-15-0402 Roberts, 2012, ATM mutations in patients with hereditary pancreatic cancer, Cancer Discov, 2, 41, 10.1158/2159-8290.CD-11-0194 Couch, 2007, The prevalence of BRCA2 mutations in familial pancreatic cancer, Cancer Epidemiol Biomarkers Prev, 16, 342, 10.1158/1055-9965.EPI-06-0783 Shindo, 2017, Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma, J Clin Oncol, 35, 3382, 10.1200/JCO.2017.72.3502 Hur, 2016, Early pancreatic ductal adenocarcinoma survival is dependent on size: positive implications for future targeted screening, Pancreas, 45, 1062, 10.1097/MPA.0000000000000587 Goggins, 2020, Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium, Gut, 69, 7, 10.1136/gutjnl-2019-319352 Corral, 2019, Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: a meta-analysis of cohort studies, Clin Gastroenterol Hepatol, 17, 41, 10.1016/j.cgh.2018.04.065 Signoretti, 2018, Results of surveillance in individuals at high-risk of pancreatic cancer: a systematic review and meta-analysis, United European Gastroenterol J, 6, 489, 10.1177/2050640617752182 Corral, 2019, Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis, Pancreas, 48, 526, 10.1097/MPA.0000000000001268 Bruenderman, 2015, A cost analysis of a pancreatic cancer screening protocol in high-risk populations, Am J Surg, 210, 409, 10.1016/j.amjsurg.2014.11.017 Joergensen, 2016, Is screening for pancreatic cancer in high-risk groups cost-effective? Experience from a Danish national screening program, Pancreatology, 16, 584, 10.1016/j.pan.2016.03.013 Rulyak, 2003, Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds, Gastrointest Endosc, 57, 23, 10.1067/mge.2003.28 2019, Screening for pancreatic cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement, JAMA, 322, 438, 10.1001/jama.2019.10232 Henrikson, 2019, Screening for pancreatic cancer: updated evidence report and systematic review for the US Preventive Services Task Force, JAMA, 322, 445, 10.1001/jama.2019.6190 Vasen, 2016, Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers, J Clin Oncol, 34, 2010, 10.1200/JCO.2015.64.0730 Canto, 2018, Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance, Gastroenterology, 155, 740, 10.1053/j.gastro.2018.05.035 Overbeek, 2022, Long-term yield of pancreatic cancer surveillance in high-risk individuals, Gut, 71, 1152, 10.1136/gutjnl-2020-323611 Overbeek, 2022, Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals, Gastroenterology, 162, 772, 10.1053/j.gastro.2021.10.014 Canto, 2020, Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic cancer, J Gastrointest Surg, 24, 1101, 10.1007/s11605-019-04230-z Paiella, 2018, Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: a systematic review and proportion meta-analysis of screening results, Pancreatology, 18, 420, 10.1016/j.pan.2018.04.002 Harinck, 2011, Feasibility of a pancreatic cancer surveillance program from a psychological point of view, Genet Med, 13, 1015, 10.1097/GIM.0b013e31822934f5 O'Neill, 2020, Long-term positive psychological outcomes in an Australian pancreatic cancer screening program, Familial Cancer, 19, 23, 10.1007/s10689-019-00147-3 Vasen, 2011, Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation, Gastroenterology, 140, 850, 10.1053/j.gastro.2010.11.048 Dbouk, 2021, Guidelines on management of pancreatic cysts detected in high-risk individuals: an evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements, Pancreatology, 21, 613, 10.1016/j.pan.2021.01.017 Suenaga, 2018, Pancreatic juice mutation concentrations can help predict the grade of dysplasia in patients undergoing pancreatic surveillance, Clin Cancer Res, 24, 2963, 10.1158/1078-0432.CCR-17-2463 Fahrmann, 2021, Lead-time trajectory of CA19–9 as an anchor marker for pancreatic cancer early detection, Gastroenterology, 160, 1373, 10.1053/j.gastro.2020.11.052 Abe, 2020, Gene variants that affect levels of circulating tumor markers increase identification of patients with pancreatic cancer, Clin Gastroenterol Hepatol, 18, 1161, 10.1016/j.cgh.2019.10.036 Kim, 2017, Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers, Sci Transl Med, 9, eaah5593, 10.1126/scitranslmed.aah5583 Zhu, 2020, Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: a meta-analysis, Cancer Med, 9, 5699, 10.1002/cam4.3276 Grunvald, 2020, Current status of circulating tumor DNA liquid biopsy in pancreatic cancer, Int J Mol Sci, 21, 7651, 10.3390/ijms21207651 Mellby, 2018, Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer, J Clin Oncol, 36, 2887, 10.1200/JCO.2017.77.6658 Liu, 2020, Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA, Ann Oncol, 31, 745, 10.1016/j.annonc.2020.02.011 Cohen, 2018, Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science, 359, 926, 10.1126/science.aar3247 Song, 2017, 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages, Cell Res, 27, 1231, 10.1038/cr.2017.106 Kenner, 2021, Artificial intelligence and early detection of pancreatic cancer: 2020 summative review, Pancreas, 50, 251, 10.1097/MPA.0000000000001762 Chu, 2019, Application of deep learning to pancreatic cancer detection: lessons learned from our initial experience, J Am Coll Radiol, 16, 1338, 10.1016/j.jacr.2019.05.034 Raptis, 2010, Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer, Surgeon, 8, 239, 10.1016/j.surge.2010.03.001 Steinberg, 1990, The clinical utility of the CA 19–9 tumor-associated antigen, Am J Gastroenterol, 85, 350 Scarà, 2015, CA 19-9: biochemical and clinical aspects, Adv Exp Med Biol, 867, 247, 10.1007/978-94-017-7215-0_15 Maithel, 2008, Preoperative CA 19–9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma, Ann Surg Oncol, 15, 3512, 10.1245/s10434-008-0134-5 Kaur, 2017, A combination of MUC5AC and CA19–9 improves the diagnosis of pancreatic cancer: a multicenter study, Am J Gastroenterol, 112, 172, 10.1038/ajg.2016.482 Chu, 2017, Diagnosis and detection of pancreatic cancer, Cancer J, 23, 333, 10.1097/PPO.0000000000000290 Provenzano, 2013, Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer, Br J Cancer, 108, 1, 10.1038/bjc.2012.569 Al-Hawary, 2014, Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association, Gastroenterology, 146, 291, 10.1053/j.gastro.2013.11.004 Tempero, 2021, Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 19, 439, 10.6004/jnccn.2021.0017 Wong, 2020, BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects, Cancer Manag Res, 12, 2731, 10.2147/CMAR.S211151 Wattenberg, 2020, Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation, Br J Cancer, 122, 333, 10.1038/s41416-019-0582-7 Golan, 2014, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers, Br J Cancer, 111, 1132, 10.1038/bjc.2014.418 O'Reilly, 2020, Randomized, multicenter, Phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation, J Clin Oncol, 38, 1378, 10.1200/JCO.19.02931 Golan, 2019, Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, N Engl J Med, 381, 317, 10.1056/NEJMoa1903387 Kasi, 2020, Update on the role of poly (ADP-ribose) polymerase inhibitors in the DNA repair-deficient pancreatic cancers: a narrative review, J Pancreat Cancer, 6, 107 Cloyd, 2017, Clinical and genetic implications of DNA mismatch repair deficiency in patients with pancreatic ductal adenocarcinoma, JAMA Surg, 152, 1086, 10.1001/jamasurg.2017.2631 Riazy, 2015, Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma, Mod Pathol, 28, 1383, 10.1038/modpathol.2015.89 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Bockorny, 2020, BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial, Nat Med, 26, 878, 10.1038/s41591-020-0880-x Byrne, 2021, Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer, Clin Cancer Res, 27, 4574, 10.1158/1078-0432.CCR-21-1047 Ghidini, 2020, Immune-based therapies and the role of microsatellite instability in pancreatic cancer, Genes, 12, 33, 10.3390/genes12010033 Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503, 548, 10.1038/nature12796 Janes, 2018, Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor, Cell, 172, 578, 10.1016/j.cell.2018.01.006 Canon, 2019, The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity, Nature, 575, 217, 10.1038/s41586-019-1694-1 Fell, 2020, Identification of the clinical development candidate MRTX849, a Covalent KRAS(G12C) inhibitor for the treatment of cancer, J Med Chem, 63, 6679, 10.1021/acs.jmedchem.9b02052 Kwan, 2022, The path to the clinic: a comprehensive review on direct KRAS(G12C) inhibitors, J Exp Clin Cancer Res, 41, 27, 10.1186/s13046-021-02225-w Hofmann, 2021, BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition, Cancer Discov, 11, 142, 10.1158/2159-8290.CD-20-0142 Krishnan, 2022, Targeting mutated KRAS genes to treat solid tumours, Mol Diagn Ther, 26, 39, 10.1007/s40291-021-00564-0 Wang, 2022, Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor, J Med Chem, 65, 3123, 10.1021/acs.jmedchem.1c01688 Ferri-Borgogno, 2020, Paradoxical role of AT-rich interactive domain 1A in restraining pancreatic carcinogenesis, Cancers (Basel), 12, 2695, 10.3390/cancers12092695 Wang, 2020, Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers, Biomed Pharmacother, 130, 110626, 10.1016/j.biopha.2020.110626 Jiang, 2020, Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes, J Cancer, 11, 776 Okamura, 2020, ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy, J Immunother Cancer, 8 Park, 2019, Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy, Clin Cancer Res, 25, 5584, 10.1158/1078-0432.CCR-18-4222 Yu, 2020, Advances and challenges of neoadjuvant therapy in pancreatic cancer, Asia Pac J Clin Oncol, 17, 425, 10.1111/ajco.13504 Muller, 2021, Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence, Pharmacology, 106, 143, 10.1159/000510343 Farren, 2020, Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy, JCI Insight, 5, 10.1172/jci.insight.130362 Turpin, 2020, Adjuvant pancreatic cancer management: towards new perspectives in 2021, Cancers (Basel), 12, 3866, 10.3390/cancers12123866 Dahan, 2021, Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial, J Clin Oncol, 39, 3242, 10.1200/JCO.20.03329 Petrioli, 2020, Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer, J Geriatr Oncol, 11, 647, 10.1016/j.jgo.2019.08.008